Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Rheumatology News International and [email protected] (Rheumatology News International). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Rheumatology News International and [email protected] (Rheumatology News International) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Episode 1: TNF-Alpha: Concept to Proof of Concept

14:53
 
Share
 

Manage episode 156760070 series 1199499
Content provided by Rheumatology News International and [email protected] (Rheumatology News International). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Rheumatology News International and [email protected] (Rheumatology News International) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Professor Sir Ravinder Maini's groundbreaking work on the characterization of TNF-alpha began in the mid-1980's with his collaboration with Professor Mark Feldman. In his study of intercellular messenger molecules, Professor Sir Maini utilized two new technologies -- protein sequencing and cDNA protein coding -- to investigate half a dozen cytokines that appeared to mediate the pathogenesis of connective tissue diseases. One of them, TNF-alpha, proved to play a pivotal role in the cascading interaction of cytokines. When antibody against TNF-alpha was produced, a new field of biologic therapy in the management of rheumatic diseases was born. In this interview, Professor Sir Maini describes the scientific discovery that earned him the title "Father of Translational Research." Listen to him describe this historic exploration in his own words. The podcast also features: Inflammation is Hallmark of Coronary Disease in RA
  continue reading

6 episodes

Artwork
iconShare
 
Manage episode 156760070 series 1199499
Content provided by Rheumatology News International and [email protected] (Rheumatology News International). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Rheumatology News International and [email protected] (Rheumatology News International) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Professor Sir Ravinder Maini's groundbreaking work on the characterization of TNF-alpha began in the mid-1980's with his collaboration with Professor Mark Feldman. In his study of intercellular messenger molecules, Professor Sir Maini utilized two new technologies -- protein sequencing and cDNA protein coding -- to investigate half a dozen cytokines that appeared to mediate the pathogenesis of connective tissue diseases. One of them, TNF-alpha, proved to play a pivotal role in the cascading interaction of cytokines. When antibody against TNF-alpha was produced, a new field of biologic therapy in the management of rheumatic diseases was born. In this interview, Professor Sir Maini describes the scientific discovery that earned him the title "Father of Translational Research." Listen to him describe this historic exploration in his own words. The podcast also features: Inflammation is Hallmark of Coronary Disease in RA
  continue reading

6 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play